primary lung cancer
Conditions
Interventions
None listed
Sponsors
Division of General Thoracic Surgery, Integrative Center of General Surgery, Gunma University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: A) Patient who underwent salvage surgery after definitive CRT/RT, stereotactic radiation, ion beam therapy. 1) Patient who underwent salvage surgery between 1/1/2010 and 12/31/2015. 2) Primary lung cancer was proven pathologically at any point in time. 3) Patient who could not complete the initial therapy because of adverse event or complication is also eligible, if the initial therapy was intended radical treatment. 4) Three years passed after salvage surgery. B) Patient who underwent salvage surgery after molecular targeted therapy(EGFR-TKI or ALK inhibitor). 1) Patient who underwent salvage surgery between 1/1/2010 and 12/31/2015. 2) Primary lung cancer was proven pathologically at any point in time. 3) EGFR-TKI or ALK inhibitor was administrated. 4) Three years passed after salvage surgery. 5) EGFR mutation status and ALK rearrangement status do not matter.
Exclusion criteria
Exclusion criteria: 1) Patient treated as induction therapy intentionally. 2) Patient who underwent resection not for local lesion (other than lung or regional lymph node). 3) Patient who was treated with molecular targeted therapy other than EGFR-TKI or ALK inhibitor as molecular targeted therapy. 4) Patient who withdrew the consent of this study. 5) Patient who was considered inappropriate to this study by attending doctor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3-year overall survival rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse event, Incidence of complications, Perioperative mortality, 3-year recurrence free survival rate, Median survival time | — |
Countries
Japan
Contacts
Public ContactYoichi Ohtaki, Kimihiro Shimizu
Gunma University Hospital Division of General Thoracic Surgery, Integrative Center of General Surgery
Outcome results
None listed